Phase 2 study of circulating microRNA biomarkers in castration-resistant prostate cancer.
Br J Cancer
; 116(8): 1002-1011, 2017 Apr 11.
Article
en En
| MEDLINE
| ID: mdl-28278515
ABSTRACT
BACKGROUND:
Biomarkers of therapeutic response and prognosis are needed to assist in the sequencing of treatments for metastatic castration-resistant prostate cancer (CRPC). Previously in a Phase 1 discovery study, we identified 14 circulating microRNAs that were associated with response to docetaxel chemotherapy or overall survival. We performed a Phase 2 validation study to verify these findings.METHODS:
Using real-time PCR, the levels of the 14 microRNAs were measured in plasma collected before and after the first cycle of docetaxel from a Phase 2 cohort of 89 patients.RESULTS:
The microRNAs were not associated with docetaxel response in the Phase 2 cohort. Higher baseline levels of six microRNAs, predominantly of the miR-200 family, were confirmed to be associated with shorter overall survival. A microRNA signature comprising these six microRNAs predicted high-risk patients in the Phase 2 cohort with a hazard ratio of 4.12 (95% CI 2.20-7.70, P=0.000001). The signature was an independent predictor in multivariable analysis with clinicopathological factors.CONCLUSIONS:
The association of circulating microRNAs with overall survival suggests their involvement in CRPC progression.
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Biomarcadores de Tumor
/
MicroARNs
/
Taxoides
/
Neoplasias de la Próstata Resistentes a la Castración
/
Antineoplásicos
Tipo de estudio:
Etiology_studies
/
Incidence_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Límite:
Adult
/
Aged
/
Aged80
/
Humans
/
Male
/
Middle aged
Idioma:
En
Año:
2017
Tipo del documento:
Article